Intermittently scanned continuous glucose monitoring is associated with high satisfaction but increased HbA1c and weight in well-controlled youth with type 1 diabetes
| Autor: | Pieter Gillard, Sara Charleer, Kelly Cammaerts, Chantal Mathieu, Kristina Casteels, Eva Vandoorne |
|---|---|
| Přispěvatelé: | Pathology/molecular and cellular medicine, Diabetes Pathology & Therapy, Diabetes Clinic |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Blood Glucose
Male Pediatrics medicine.medical_specialty Adolescent Child preschool Glycated Hemoglobin A/metabolism Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Hypoglycemic Agents/therapeutic use Hypoglycemia 03 medical and health sciences body weight 0302 clinical medicine Quality of life Diabetes mellitus Blood Glucose Self-Monitoring/methods Internal Medicine medicine Clinical endpoint Hypoglycemic Agents Humans 030212 general & internal medicine Prospective Studies Child Quality Of Life Glycemic Glycated Hemoglobin Type 1 diabetes Blood Glucose/metabolism business.industry Blood Glucose Self-Monitoring Diabetes Mellitus Type 1/blood medicine.disease Diabetes Mellitus Type 1 Pediatrics Perinatology and Child Health Absenteeism Observational study Female business |
| Popis: | OBJECTIVE: We undertook a 24-month prospective observational single-center real-world trial to study impact of access to intermittently scanned continuous glucose monitoring (isCGM) on quality of life (QOL) and glycemic control of youth with type 1 diabetes (T1D). METHODS: Between September 2016 and November 2017, 138 children and adolescents with T1D were recruited. Demographic, metabolic, and QOL data were collected during 24 months of routine follow-up. Primary endpoint was the evolution of QOL, with secondary outcomes change in HbA1c, occurrence of acute diabetes complications, and school absenteeism. RESULTS: Ninety-two percent of participants found isCGM more user-friendly than capillary finger-stick tests and had high treatment satisfaction, without change in diabetes-specific QOL. HbA1c significantly increased from 7.2% (7.0-7.3) (55 mmol/mol [53-56]) at baseline to 7.6% (7.4-7.8) (60 mmol/mol [57-62]) at 12 months (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|